The two entities will collaborate on work focused on "fields of energy and climate; quantum computing and artificial intelligence; global health and medicine; and urban futures." Photo via Rice University

Rice University and Université Paris Sciences & Lettres signed a strategic partnership agreement last week that states that the two institutions will work together on research on some of today's most pressing subject matters.

According to an announcement made on May 13 in Paris, the two schools and research hubs will collaborate on work focused on "fields of energy and climate; quantum computing and artificial intelligence; global health and medicine; and urban futures."

The partnership allows Rice to expand its presence in France, after launching its Rice Global Paris Center about two years ago.

Université PSL consists of 11 top research institutes in France and 2,900 world-class researchers and 140 research laboratories.

“We are honored and excited to partner with Paris Sciences and Lettres University and join forces to advance bold innovation and find solutions to the biggest global challenges of our time,” Rice President Reginald DesRoches said in a statement. “The unique strengths and ambitions of our faculty, students, scholarship and research are what brings us together, and our passion and hope to build a better future for all is what will drive our partnership agenda. Representing two distinct geographic, economic and cultural regions known for ingenuity and excellence, Rice and PSL’s efforts will know no bounds.”

Rice and Université PSL plan to host conferences around the four research priorities of the partnership. The first took place last week at the Rice Global Paris Center. The universities will also biannually select joint research projects to support financially.

“This is a global and cross-disciplinary partnership that will benefit from both a bottom-up, research-driven dynamic and a top-down commitment at the highest level,” PSL President Alain Fuchs said in a statement. “The quality and complementarity of the researchers from PSL and Rice who mobilized for this event give us reason to believe that this partnership will get off to a rapid and productive start. It will offer a strong framework to all the PSL schools for developing collaborations within their areas of strength and their natural partners at Rice.”

Rice launched its Rice Global Paris Center in June 2022 in a historic 16th-century building in Le Marais. At the time it, the university shared that it was intended to support Rice-organized student programs, independent researchers, and international conferences, as well as a satellite and hub for other European research activity.

"Rice University's new home in the Marais has gone from an idea to a mature relative with a robust program of faculty research summits, student opportunities, cultural events and community engagement activities," Caroline Levander, Rice's global Vice President, said at the announcement of the partnership last week.

Click here to learn more about the Global Paris Center.

Last month, University of Houston also signed a memorandum of understanding with Heriot-Watt University in Scotland to focus on hydrogen energy solutions.

------

This article originally ran on EnergyCapital.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.